Alnylam reports positive topline 18-month results from helios-a phase 3 study of vutrisiran in patients with hattr amyloidosis with polyneuropathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the helios-a phase 3 study of vutrisiran, an investigational rnai therapeutic in development for the treatment of the polyneuropathy associated with hereditary transthyretin-mediated (hattr) amyloidosis, met all secondary endpoints measured at 18 months, including statistically significant improvements in neuropathy as measured by the modified neuropathy i
ALNY Ratings Summary
ALNY Quant Ranking